Evoke Pharma
EVOK
EVOK was delisted on the 16th of December, 2025.
8 hedge funds and large institutions have $966K invested in Evoke Pharma in 2024 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 5 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
3% less capital invested
Capital invested by funds: $995K → $966K (-$29K)
10.74% less ownership
Funds ownership: 25.4% → 14.66% (-11%)
33% less funds holding
Funds holding: 12 → 8 (-4)
80% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$458K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$5.82K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
-$339K |
| 2 |
CCM
Corsair Capital Management
New York
|
-$55.5K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
-$3.88K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$80 |
| 5 |
Citigroup
New York
|
-$20 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
NCM
1
Nantahala Capital Management
New Canaan,
Connecticut
| $655K | +$458K | +91,945 | +163% |
|
|
BL
2
Bleichroeder LP
New York
| $304K | – | – | – |
|
|
3
UBS Group
Zurich,
Switzerland
| $5.56K | +$5.82K | +1,168 | +1,298% |
|
4
BlackRock
New York
| $539 | – | – | – |
|
|
SS
5
SBI Securities
Tokyo,
Japan
| $332 | +$374 | +75 | New |
|
6
Morgan Stanley
New York
| $137 | – | – | – |
|
|
NA
7
NewEdge Advisors
New Orleans,
Louisiana
| $75 | – | – | – |
|
|
8
Bank of America
Charlotte,
North Carolina
| $40 | -$80 | -16 | -64% |
|
|
ACM
9
AIGH Capital Management
Baltimore,
Maryland
| – | -$339K | -70,546 | Closed |
|
|
CCM
10
Corsair Capital Management
New York
| – | -$55.5K | -11,667 | Closed |
|
|
TRCT
11
Tower Research Capital (TRC)
New York
| – | -$3.88K | -816 | Closed |
|
|
12
Citigroup
New York
| – | -$20 | -4 | Closed |
|
|
DB
13
Danske Bank
Copenhagen K,
Denmark
| – | -$10 | -2 | Closed |
|
EVOK Hedge Fund Activity: Q4 2024 in Review
8 of the 7,597 institutional investors tracked by Wall St. Rank reported a position in Evoke Pharma (EVOK) for Q4 2024, worth a combined $966K — down 2.9% from $995K a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of EVOK and 1 opened new positions — a net loss of 4 holders — while 1 trimmed existing stakes and 2 added.
The largest buyer was Nantahala Capital Management, adding an estimated $458K. The largest seller was AIGH Capital Management, exiting entirely with an estimated $339K sold.
- 8 institutional investors held Evoke Pharma (EVOK) as of Q4 2024, down from 12 in Q3 2024.
- Funds reported $966K of Evoke Pharma stock for Q4 2024, down 2.9% quarter-over-quarter.
- 1 fund opened new Evoke Pharma positions in Q4 2024 and 5 closed out, a net change of -4 holders.
- The largest Evoke Pharma buyer in Q4 2024 was Nantahala Capital Management, an estimated $458K added.
- The largest Evoke Pharma seller in Q4 2024 was AIGH Capital Management, an estimated $339K sold.
Based on aggregated 13F filings for Q4 2024.